Treatment of migraine headache
AssigneePozen Inc.
InventorsJohn R. Plachetka, Zakauddin T. Chowhan
Life of this patent
Estimating the term…
Abstract
This invention comprises a non-vasoactive, supra-vasoactive syndrome ("SVS") minimized dosage form for treatment of migraine in a human comprising (i) rapid availability metoclopramide in at least about an effective local gastrointestinal amount; (ii) at least one long acting NSAID such as naproxen sodium in a therapeutically effective amount; (iii) wherein said dosage form is a coordinated dosage form; and, (iv) wherein the dosage form is absent 5HT agonist vasoactive agents, and preparation thereof. Acid-base stable dosage forms are noted. This invention further comprises methods of migraine treatment, and methods for rapid introduction of oral NSAID into the small bowel.
Claims9
An acid-base storage stable, uniform-coated, non-vasoactive, supra-vasoactive syndrome ("SVS") minimized, pharmaceutical unit dosage form for treatment of migraine in a human comprising:
- (i) means for providing rapid availability metoclopramide to said humane upon administration in at least an effective local gastrointestinal amount for said treatment and
- (ii) means for providing at least one long acting NSAID to said human upon administration in a therapeutically effective amount for said treatment
- wherein said dosage form is a coordinated dosage form, and wherein the dosage form is absent 5HT agonist vasoactive agents.
An acid-base storage stable, uniform-coated, non-vasoactive, supra-vasoactive syndrome ("SVS") minimized, pharmaceutical unit dosage form for treatment of migraine in a human comprising:
- (i) a first layer containing an NSAID in granular form uniformly distributed throughout a matrix of pharmaceutically acceptable fillers, excipients, binding agents, disintegrants, and lubricants, surrounded by
- (ii) a second layer having an interior and exterior portion, and having metoclopramide in crystalline form uniformly distributed throughout the exterior portion of said second layer wherein said interior portion comprises an interface between the exterior portion of said second layer the first layer, and wherein,
- (iii) said interior portion comprises from about 1% to about 15% of total tablet coating of said second layer.
A method of manufacturing a unit dosage form for treatment of migraine in a human comprising
- (i) forming over an NSAID core a coating layer having an interior and exterior portion by the steps of;
- (ii) applying as the interior portion of said layer a coating of a weight equal to from about 1% to about 8% of the core weight, wherein said coating is a pharmaceutically acceptable coating material and said coating material is absent metoclopramide;
- and thereafter
- (iii) drying said interior portion;
- and thereafter,
- (iv) applying over said dried interior portion an exterior portion comprising a coating of a weight equal to from about 6% to about 15% of the core weight, wherein said coating comprises metoclopramide uniformly distributed throughout said exterior portion.
The method of 6 wherein said rotating is agitating rotating.
The method of 8 wherein said rotating is agitating rotating.
Dependencies are inferred from the claim text.